

European Business Development Conference

Big Deals, Big Data, Better Drugs
7 and 8 October 2014 / Dresden / Germany

Company Profile: CureVac GmbH

Contact Person: Dr. Achim Loehr, Director Business Development
Address / PO Box: CureVac GmbH, Paul-Ehrlich-Str. 15
Postal Code / City: 72076 Tübingen
State:
Country: Germany
Telephone: +49 (0) 7071 920 53-196
Fax:
E-mail Address: achim.loehr@curevac.com
Website: www.curevac.com
Existing co-operations: Boehringer Ingelheim, Sanofi Pasteur, DARPA, Janssen Pharmaceuticals, Ludwig Cancer Research and the Bill & Melinda Gates Foundation
Request for co-operations: Parties interested in utilization of our innovative mRNA platform to develop next generation vaccines and therapeutics.
<p>CureVac is the leading RNA company with the longest and broadest experience worldwide to develop mRNA-based drugs. CureVac develops next generation cancer immunotherapies and prophylactic vaccines against infectious diseases based on mRNA – both under the brand RActive® – by using the body to produce its own drugs. Furthermore, CureVac develops an innovative adjuvant (RNAAdjuvant®) based on non-coding RNA which significantly enhances the immune response of other vaccines. The company deploys unique capabilities to tailor and optimize unmodified, target-specific mRNA in order to design drugs with truly transformative potential. CureVac successfully brought the first mRNA-based drugs into the clinic with several hundred patients treated and established a robust and scalable GMP process in its own facility. CureVac proved to be capable to develop new drugs from concept to IND in a fraction of time as compared to standard timelines and thereby increasing significantly the R&D productivity. Numerous strategic collaborations with leaders in the field validate the concept. Among those are Boehringer Ingelheim, Sanofi Pasteur, DARPA, Janssen, Ludwig Cancer Research and the Bill & Melinda Gates Foundation.</p>